Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles

Journal of General Virology

Volumn 83, Issue 2, 2002, Pages 369-381

  Brinster, C ^a   Chen, M ^a   Boucreux, D ^a   Paranhos Baccala, G ^a   Liljestrom P ^a   Lemmonier, F ^a   Inchauspe G ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLASMID DNA; PROTEIN ANTIBODY; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG EFFICACY; FEMALE; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SEMLIKI FOREST ALPHAVIRUS; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ALPHAVIRUS; ANIMALIA; HEPATITIS C VIRUS; MURINAE; MUS MUSCULUS; RNA VIRUSES; SEMLIKI FOREST VIRUS;

EID: 0036166630     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-2-369     Document Type: Article

References (70)

1. Transmissible agent in non-A, non-B hepatitis
2. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
3. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection
4. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
5. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
6. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate
7. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
8. Enhancing immune responses using suicidal DNA vaccines
9. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
10. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
11. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
12. DNA vaccines for hepatitis C virus
13. Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope
14. Cellular HIV-1 immune responses in natural infection and after genetic immunization
15. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
16. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
17. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis
18. Vaccination of chimpanzees against infection by the hepatitis C virus
19. The scientific challenge of hepatitis C
20. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene
21. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus
22. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7
23. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
24. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
25. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
26. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge
27. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
28. + T-cell response in acute hepatitis C
29. Death mechanisms in cultured cells infected by Semliki Forest virus
30. Expression and identification of hepatitis C virus polyprotein cleavage products
31. Hepatitis C: The clinical spectrum of disease
32. Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates
33. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor
34. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters
35. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
36. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
37. + T cells: Implications for vaccine development
38. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
39. Analysis of a successful immune response in persons infected with hepatitis C virus
40. DNA and RNA-based vaccines: Principles, progress and prospects
41. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells
42. Expression of proteins using Semliki Forest virus vectors
43. DNA immunization protects nonhuman primates against rabies virus
44. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization
45. Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides
46. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus
47. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
48. Protection against lethal simian immunodeficiency virus SIV smmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
49. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode
50. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
51. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
52. b β2m double knockout mice
53. Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles
54. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
55. + T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection
56. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
57. Semliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells
58. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
59. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
60. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
61. Hepatitis C virus non structural protein NS3 transforms NIH 3T3 cells
62. Togaviridae: The viruses and their replication
63. Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein
64. Internal processing of hepatitis C virus NS3 protein
65. Two-helper RNA system for production of recombinant Semliki Forest virus particles
66. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice
67. Oral immunization with HCV-NS3 encoding salmonella: Long-lasting induction of HCV-specific CTL in an HLA-A2 transgenic mouse model
68. + cytotoxic T-cell epitopes
69. Cancer therapy using a self-replicating RNA vaccine
70. Generation of cytotoxic and humoral immune responses by non-replicative recombinant Semliki Forest virus